StreetInsider.com News Articles

Raymond James Upgrades Profound Medical Corp. (PROF) to Strong Buy, 'we see a nonzero probability of TULSA delivering superior results'

Mon, 27 Jul 2026 13:06:03 -0400

(Updated - July 27, 2026 1:06 PM EDT)

Raymond James analyst Michael Freeman upgraded Profound Medical Corp. (NASDAQ: PROF) from Outperform to Strong Buy with a price target of $11.00.

The analyst comments "Here we review positive incremental data from the CAPTAIN trial, positive TULSA reimbursement developments (2027 CMS Proposed Rules), and flag upcoming catalysts. Based on these positive developments and in anticipation of a strong 2H26, we upgrade PROF to Strong Buy and maintain our US$11 PT. CAPTAIN Trial: TULSA Superior vs. Robotic RP on Basis of Penile Length Reduction (1-Month) PROF released positive incremental data from its CAPTAIN trial (TULSA

Raymond James Upgrades Profound Medical Corp. (PROF) to Strong Buy, 'we see a nonzero probability of TULSA delivering superior results'

Mon, 27 Jul 2026 13:06:03 -0400

(Updated - July 27, 2026 1:06 PM EDT)

Raymond James analyst Michael Freeman upgraded Profound Medical Corp. (NASDAQ: PROF) from Outperform to Strong Buy with a price target of $11.00.

Raymond James Upgrades Profound Medical Corp. (PROF) to Strong Buy, 'we see a nonzero probability of TULSA delivering superior results'

Mon, 27 Jul 2026 13:06:03 -0400

(Updated - July 27, 2026 1:06 PM EDT)

Raymond James analyst Michael Freeman upgraded Profound Medical Corp. (NASDAQ: PROF) from Outperform to Strong Buy with a price target of $11.00.

Raymond James Upgrades Profound Medical Corp. (PROF) to Strong Buy, 'we see a nonzero probability of TULSA delivering superior results'

Mon, 27 Jul 2026 13:06:03 -0400

(Updated - July 27, 2026 1:06 PM EDT)

Raymond James analyst Michael Freeman upgraded Profound Medical Corp. (NASDAQ: PROF) from Outperform to Strong Buy with a price target of $11.00.

Form 8-K Profound Medical Corp. For: Jul 24

Fri, 24 Jul 2026 12:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26812392.html

Form 8-K Profound Medical Corp. For: Jul 24

Fri, 24 Jul 2026 12:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26812392.html

Form 8-K Profound Medical Corp. For: Jul 16

Thu, 16 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260716/26780294.html

Form 8-K Profound Medical Corp. For: Jul 16

Thu, 16 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260716/26780294.html

Form 8-K Profound Medical Corp. For: Jul 15

Wed, 15 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260715/26771198.html

Form 8-K Profound Medical Corp. For: Jul 15

Wed, 15 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260715/26771198.html

Form EFFECT Profound Medical Corp.

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524303.html

Form EFFECT Profound Medical Corp.

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524303.html

Form 8-K Profound Medical Corp. For: May 13

Fri, 15 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26505228.html

Form 8-K Profound Medical Corp. For: May 13

Fri, 15 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26505228.html

Telix partners with EDAP and Profound on prostate imaging tech

Fri, 15 May 2026 06:31:09 -0400

Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.

The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.